×
Hero Background

Dravet Syndrome Companies

ID: MRFR/Pharma/4062-HCR
85 Pages
Rahul Gotadki
October 2025

Dravet Syndrome companies specialize in the research and development of therapies and interventions for this rare and severe form of epilepsy. These organizations play a vital role in improving the quality of life for individuals affected by Dravet Syndrome.

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Dravet Syndrome Market Research Report– Forecast till 2035 Infographic
Summary Table of Contents Segmentation Download PDF

Top Industry Leaders in the Dravet Syndrome Market

Dravet Syndrome Market

 

Latest Dravet Syndrome Companies Updates


Stoke Therapeutics (NASDAQ: STOK): Presented positive data from their Phase 2 open-label extension study of STK-001, an antisense oligonucleotide therapy targeting the SCN1A gene mutation responsible for Dravet Syndrome.


Eisai Inc.: Initiated a Phase 3 clinical trial called Momentum I to study the efficacy of lorcaserin as an adjuctive (add-on) treatment in Dravet Syndrome to reduce seizure frequency.


Encoded Therapeutics: Collaborating with Cook Children's Medical Center on a non-interventional study to identify potential biomarkers for Dravet Syndrome using GABA levels in the blood.


Zogenix Inc.: Partnered with the DSF to provide educational grants to healthcare professionals on the use of Fintepla (fenfluramine) for Dravet Syndrome treatment.


List of Dravet Syndrome Key companies in the market:



  • Biocodex

  • Biscayne Neurotherapeutics

  • Cyberonics

  • Epygenix Therapeutics

  • GW Pharmaceuticals

  • INSYS THERAPEUTICS

  • OPKO Health Inc.

  • Ovid Therapeutics

  • PTC Therapeutics